11:37 AM EST - Cardiome Pharma Corp. : Announced today that it received authorization from the French Transparency Pricing Commission to begin selling XYDALBA in France and that it has subsequently launched XYDALBA in France. The European Medicines Agency (EMA) approved XYDALBA in 2015 for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and the single dose administration was approved in 2016. Cardiome Pharma Corp.
shares T.COM are trading up $0.05 at $4.10.
